CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30...
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders
CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent...
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
CNS Pharmaceuticals (NASDAQ: CNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at...
CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent...
CNS Pharmaceuticals (NASDAQ: CNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities...
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced...